What I would say, just for clarification, is that with regard to Medicago there are two laneways. Laneway number one is the negotiation of these doses that was done under these advance purchase agreements. That's led by Public Services and Procurement, working closely with the Health portfolio. Then there's our work with the company to actually support the development of the vaccine and to support the expansion of their facility in Canada. That's principally us.
I'd certainly be happy to talk a bit about the work we did to support them in developing the vaccine and building out their facility in Quebec City, but we were not directly involved. It's not really our authority, the dose purchases, the actual purchase of the vaccine.